ArticleJournal of the American Heart Association2019
NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study.
Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.Hypertension (Dallas, Tex. : 1979) · 2024Trial
- Analysis of factors associated with cognitive impairment in elderly patients hospitalized with chronic heart failure.Frontiers in medicine · 2026Article
- Prevalence of high N-terminal prohormone of brain natriuretic peptide levels and associated factors among community-dwelling older adults aged over 75 years (The SONIC study): a cross-sectional study.BMC research notes · 2025Article
- Identifying suppressive factors of Alzheimer's disease through comprehensive analysis of real-world data: a single-center retrospective study.BMC geriatrics · 2025Article
- Attention as the primary cognitive domain affected in post-myocardial infarction cognitive impairment: a prospective multicenter study.Scientific reports · 2025Article
- Factors Influencing the Development and Severity of Cognitive Decline in Patients with Chronic Heart Failure.Medicina (Kaunas, Lithuania) · 2024Article
- Exploring the possible causal effects of cardiac blood biomarkers in dementia and cognitive performance: a Mendelian randomization study.GeroScience · 2023Article
- Cognitive Impairment in Heart Failure-A Review.Biology · 2022Review
- Atrial cardiopathy and cognitive impairment.Frontiers in aging neuroscience · 2022Review
- Concurrent cardiac transthyretin and brain β amyloid accumulation among the older adults: The Hisayama study.Brain pathology (Zurich, Switzerland) · 2022Article
- Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study.BMC geriatrics · 2021Observational
- Prediction of Cognitive Decline Using Heart Rate Fragmentation Analysis: The Multi-Ethnic Study of Atherosclerosis.Frontiers in aging neuroscience · 2021Article
- Growth Differentiation Factor 15 and NT-proBNP as Blood-Based Markers of Vascular Brain Injury and Dementia.Journal of the American Heart Association · 2020Article
- Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension.Journal of clinical medicine · 2020Review
- NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study.Journal of the American Heart Association · 2019Article
- What's New in Dementia Risk Prediction Modelling? An Updated Systematic Review.Dementia and geriatric cognitive disorders extraReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Epidemiological evidence implies a link between heart disease and dementia. However, few prospective studies have assessed the association between serum NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels and dementia. Methods and Results A total of 1635 community-dwelling Japanese elderly aged ≥60 years without dementia (57% women, mean age±SD 70.8±7.7 years) were followed up for 10 years. Serum NT-proBNP levels were divided into 4 categories (≤54, 55-124, 125-299, and ≥300 pg/mL). The hazard ratios were estimated using a Cox proportional hazards model. During the follow-up period, 377 subjects developed all-cause dementia, 247 Alzheimer disease, and 102 vascular dementia. The age- and sex-adjusted incidence of all-cause dementia was 31.5 per 1000 person-years and increased significantly with higher serum NT-proBNP levels, being 16.4, 32.0, 35.7, and 45.5, respectively (P for trend <0.01). Subjects with serum NT-proBNP levels of ≥300 pg/mL had a significantly higher risk of all-cause dementia (hazard ratio=2.46, 95% CI 1.63-3.71) than those with serum NT-proBNP levels of ≤54 pg/mL after adjusting for confounders. Similar risks were observed for Alzheimer disease and vascular dementia. Incorporation of the serum NT-proBNP level into a model with known risk factors for dementia significantly improved the predictive ability for incident dementia (c-statistics 0.780-0.787, P=0.02; net reclassification improvement 0.189, P=0.001; integrated discrimination improvement 0.011, P=0.003). Conclusions Higher serum NT-proBNP levels were significantly associated with an increased risk of dementia. Serum NT-proBNP could be a novel biomarker for predicting future risk of dementia in the general elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.